Teachers Retirement System of The State of Kentucky lowered its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 1.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 236,862 shares of the biopharmaceutical company’s stock after selling 3,160 shares during the quarter. Teachers Retirement System of The State of Kentucky owned 0.11% of Alexion Pharmaceuticals worth $28,326,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in ALXN. Delpha Capital Management LLC bought a new position in Alexion Pharmaceuticals during the fourth quarter valued at about $102,000. Valeo Financial Advisors LLC purchased a new stake in shares of Alexion Pharmaceuticals during the third quarter valued at $147,000. Dupont Capital Management Corp purchased a new stake in shares of Alexion Pharmaceuticals during the third quarter valued at $156,000. Beacon Investment Advisory Services Inc. purchased a new stake in shares of Alexion Pharmaceuticals during the third quarter valued at $201,000. Finally, Invictus RG purchased a new stake in shares of Alexion Pharmaceuticals during the third quarter valued at $202,000. 95.38% of the stock is owned by institutional investors and hedge funds.
Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at $125.68 on Monday. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.62. Alexion Pharmaceuticals, Inc. has a 52-week low of $96.18 and a 52-week high of $149.34. The firm has a market capitalization of $27,860.00, a PE ratio of 57.92, a price-to-earnings-growth ratio of 1.16 and a beta of 1.13.
Several brokerages have recently commented on ALXN. Cowen reaffirmed a “buy” rating and set a $163.00 target price on shares of Alexion Pharmaceuticals in a report on Friday. BMO Capital Markets upped their target price on Alexion Pharmaceuticals from $177.00 to $180.00 and gave the company an “outperform” rating in a report on Friday, February 9th. Deutsche Bank set a $161.00 target price on Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Friday, February 9th. ValuEngine downgraded Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, March 1st. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $151.00 price objective on shares of Alexion Pharmaceuticals in a research note on Friday, February 9th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and twenty have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $154.64.
In other news, CEO Ludwig Hantson sold 2,553 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total transaction of $310,521.39. Following the transaction, the chief executive officer now owns 36,172 shares of the company’s stock, valued at approximately $4,399,600.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP John B. Moriarty sold 3,363 shares of the stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $115.70, for a total value of $389,099.10. Following the transaction, the executive vice president now directly owns 71,400 shares in the company, valued at approximately $8,260,980. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 31,253 shares of company stock worth $3,656,229. Insiders own 4.35% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/03/12/teachers-retirement-system-of-the-state-of-kentucky-decreases-position-in-alexion-pharmaceuticals-inc-alxn.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.